Principal Financial Group
SLNO

Principal Financial Group’s Soleno Therapeutics SLNO Stock Holding History

Principal Financial Group’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,197
Closed -$216K – 2260
2025
Q3 		$216K Buy
3,197
+340
+12% +$25.2K ﹤0.01% 2162
2025
Q2 		$239K Buy
+2,857
New +$214K ﹤0.01% 2108
2021
Q2 		– Sell
-715
Closed -$14K – 2643
2021
Q1 		$14K Sell
715
-117
-14% -$3.77K ﹤0.01% 2479
2020
Q4 		$24K Buy
+832
New +$24K ﹤0.01% 2408

Other funds holding SLNO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Principal Financial Group's SLNO Position: Q4 2025 in Review

Principal Financial Group sold out of Soleno Therapeutics (SLNO) in Q4 2025, closing a stake of 3,197 shares — an estimated $216K sold.

Principal Financial Group first reported a position in SLNO in Q4 2020 and held it in 4 quarters. The position peaked at $239K in Q2 2025. 248 funds tracked by Wall St. Rank hold SLNO as of Q4 2025.

  • Principal Financial Group reported no remaining Soleno Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Principal Financial Group sold 3,197 Soleno Therapeutics shares in Q4 2025, an estimated $216K.
  • Principal Financial Group first reported a position in Soleno Therapeutics in Q4 2020 and held it in 4 quarters.
  • Principal Financial Group's Soleno Therapeutics position peaked at $239K in Q2 2025.
  • 248 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q4 2025.

Based on Principal Financial Group's 13F filing for Q4 2025, filed 2 Feb 2026.